Multidisciplinary Approaches to the Management of Atopic Dermatitis : Episode 6

Real-World Challenges to Providing Evidence-Based Care for Atopic Dermatitis

February 3, 2025

Opinion

Video

Panelists discuss the 2023 American Academy of Allergy, Asthma & Immunology/ American College of Allergy, Asthma & Immunology (AAAAI/ACAAI) Joint Task Force guidelines, highlighting treatment options with strong recommendations and high certainty of evidence, including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib) for atopic dermatitis management.

EP: 1.Overview of Atopic Dermatitis Pathophysiology and Atopic March in Children

EP: 2.Considerations for Diagnosing Atopic Dermatitis and Assessing Severity

EP: 3.Exploring the Pediatric Patient and Caregiver Journey

EP: 4.Multidisciplinary Approaches to Atopic Dermatitis Management and Referrals

EP: 5.Setting Goals for Pediatric Atopic Dermatitis Treatment

Now Viewing

EP: 6.Real-World Challenges to Providing Evidence-Based Care for Atopic Dermatitis

EP: 7.Navigating New Treatment Options for Pediatric Atopic Dermatitis Management

EP: 8.Managing Comorbidities and Mitigating Atopic March in Adolescent and Adult Patients

EP: 9.Expectations for Efficacy and Duration of Response With Systemic Atopic Dermatitis Treatments

EP: 10.Considerations for Switching Systemic Agents in Atopic Dermatitis

EP: 11.Future Directions in the Treatment of Pediatric Atopic Dermatitis

EP: 12.Patient and Caregiver Advice for Navigating Atopic Dermatitis

EP: 13.Key Takeaways on the Evolving Landscape of Pediatric Atopic Dermatitis Treatment

Video content above is prompted by the following:

2023 AAAAI/ACAAI Joint Task Force Practice Parameters and Guidelines (Ann Allergy Asthma Immunol 2024;132:274-312).
Discuss the treatment options with strong recommendations and high certainty of evidence.
Biologics/monoclonal antibodies: dupilumab, tralokinumab, lebrikizumab
JAK inhibitors: abrocitinib, baricitinib, upadacitinib

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!